You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Moodys
McKesson
Johnson and Johnson
Express Scripts
McKinsey

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

RITUXAN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for RITUXAN

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Merck Sharp & Dohme Corp.Phase 1/Phase 2
Rutgers, The State University of New JerseyPhase 2
Deepa JagadeeshPhase 2

See all RITUXAN clinical trials

Recent Litigation for RITUXAN

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Ravgen, Inc. v. PerkinElmer Inc.2020-06-01
Ravgen, Inc. v. Natera, Inc.2020-06-01
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12

See all RITUXAN litigation

PTAB Litigation
PetitionerDate
Celltrion, Inc.2018-05-04
Apotex Inc.2018-02-23
2018-01-08

See all RITUXAN litigation

Pharmacology for RITUXAN

Patent Text Search: US Patents for RITUXAN

These patents were identified by searching patent claims

Supplementary Protection Certificates for RITUXAN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
15C0029 France   Start Trial PRODUCT NAME: IBRUTINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/14/945 20141023
LUC00044 Luxembourg   Start Trial PRODUCT NAME: INOTUZUMAB OZOGAMICINE ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (BESPONSA ); AUTHORISATION NUMBER AND DATE: EU/1/17/1200 20170703
1590021-0 Sweden   Start Trial PRODUCT NAME: IBRUTINIB ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/14/945 20141023
132017000135500 Italy   Start Trial PRODUCT NAME: SARILUMAB(KEVZARA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1196, 20170627
CA 2017 00012 Denmark   Start Trial PRODUCT NAME: IBRUTINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 C(2015)4704 20150707
PA2020505 Lithuania   Start Trial PRODUCT NAME: UPADACITINIBAS; REGISTRATION NO/DATE: EU/1/19/1404 20191216
122015000013 Germany   Start Trial PRODUCT NAME: POMALIDOMID UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE, HYDRATE ODER STEREOISOMERE (IMNOVID); REGISTRATION NO/DATE: EU/1/13/850 20130805
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
McKinsey
Baxter
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.